- Home
- FLNG vs CVAC Comparison
FLNG vs CVAC Comparison
Compare FLNG & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNG
- CVAC
- Stock Information
- Founded
- FLNG 2006
- CVAC 2000
- Country
- FLNG Bermuda
- CVAC Germany
- Employees
- FLNG N/A
- CVAC N/A
- Industry
- FLNG Marine Transportation
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- FLNG Consumer Discretionary
- CVAC Health Care
- Exchange
- FLNG Nasdaq
- CVAC Nasdaq
- Market Cap
- FLNG 1.3B
- CVAC 1.2B
- IPO Year
- FLNG N/A
- CVAC 2020
- Fundamental
- Price
- FLNG $24.94
- CVAC $5.36
- Analyst Decision
- FLNG Hold
- CVAC Hold
- Analyst Count
- FLNG 1
- CVAC 3
- Target Price
- FLNG $23.00
- CVAC $6.83
- AVG Volume (30 Days)
- FLNG 599.1K
- CVAC 475.8K
- Earning Date
- FLNG 11-11-2025
- CVAC 11-11-2025
- Dividend Yield
- FLNG 12.04%
- CVAC N/A
- EPS Growth
- FLNG N/A
- CVAC N/A
- EPS
- FLNG 1.83
- CVAC 1.01
- Revenue
- FLNG $355,837,000.00
- CVAC $599,540,810.00
- Revenue This Year
- FLNG N/A
- CVAC N/A
- Revenue Next Year
- FLNG $3.41
- CVAC $23.95
- P/E Ratio
- FLNG $13.54
- CVAC $5.32
- Revenue Growth
- FLNG N/A
- CVAC 675.15
- 52 Week Low
- FLNG $19.46
- CVAC $2.37
- 52 Week High
- FLNG $27.67
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- FLNG 41.83
- CVAC 46.28
- Support Level
- FLNG $24.65
- CVAC $5.32
- Resistance Level
- FLNG $25.90
- CVAC $5.41
- Average True Range (ATR)
- FLNG 0.58
- CVAC 0.04
- MACD
- FLNG -0.27
- CVAC -0.00
- Stochastic Oscillator
- FLNG 9.44
- CVAC 44.44
About FLNG FLEX LNG Ltd.
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The fleet consists of thirteen modern LNG ships, ten existing and three under construction for delivery. All LNG carriers are equipped with slow-speed, two-stroke engines MEGI or X-DF propulsion which will provide Charterers with tonnage offering advantages in form of reduced fuel consumption and lowered boil-off rates.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.